AVALYN PHARMA INC (AVLN) competitors & alternatives
Health Care · NASDAQ
AVALYN PHARMA INC (AVLN)'s top competitors and alternatives — its most similar public companies — include RAPPORT THERAPEUTICS INC (RAPP), REZOLUTE INC (RZLT), CULLINAN THERAPEUTICS INC (CGEM), PRELUDE THERAPEUTICS INC (PRLD), ELEDON PHARMACEUTICALS INC (ELDN), MAPLIGHT THERAPEUTICS INC (MPLT), MONOPAR THERAPEUTICS INC (MNPR), RELAY THERAPEUTICS INC (RLAY), VOR BIOPHARMA INC (VOR), ANAPTYSBIO INC (ANAB), EVOMMUNE INC (EVMN) and TENAX THERAPEUTICS INC (TENX). These are AVALYN PHARMA INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top AVLN competitors & alternatives
-
RAPPORT THERAPEUTICS INCRAPPHealth Care
Rapport Therapeutics is a clinical-stage biotechnology company using a proprietary precision medicine platform to develop targeted therapies for complex…
$41.33 (as of 2026-07-22) · market cap $2.1B
-
REZOLUTE INCRZLTHealth Care
Rezolute is a clinical-stage biopharmaceutical company developing targeted therapeutic solutions for rare and chronic metabolic and endocrine diseases.
$5.00 (as of 2026-07-22) · market cap $481M
-
CULLINAN THERAPEUTICS INCCGEMHealth Care
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing targeted, innovative therapies for cancer and autoimmune diseases.
$17.65 (as of 2026-07-22) · market cap $1.1B
-
PRELUDE THERAPEUTICS INCPRLDHealth Care
An early-stage biopharma company developing novel small-molecule drug candidates targeting protein-driven disease mechanisms.
$3.92 (as of 2026-07-22) · market cap $313M
-
ELEDON PHARMACEUTICALS INCELDNHealth Care
Eledon Pharmaceuticals is a clinical-stage biotech developing immune-modulating therapies for autoimmune diseases and organ transplantation.
$3.72 (as of 2026-07-22) · market cap $287M
-
MAPLIGHT THERAPEUTICS INCMPLTHealth Care
MapLight Therapeutics is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel, targeted treatments for central nervous…
$35.31 (as of 2026-07-22) · market cap $1.6B
-
MONOPAR THERAPEUTICS INCMNPRHealth Care
Monopar Therapeutics is a clinical-stage biopharmaceutical firm focused on developing innovative radiopharmaceuticals for cancer and specialized treatments for…
$112.48 (as of 2026-07-22) · market cap $752M
-
RELAY THERAPEUTICS INCRLAYHealth Care
A precision medicine company using computational drug discovery to target protein motion and advance a pipeline of novel small molecule therapeutics.
$19.27 (as of 2026-07-22) · market cap $4.2B
-
VOR BIOPHARMA INCVORHealth Care
Vor Biopharma is a clinical-stage biopharmaceutical company developing advanced cell therapy and gene therapy solutions for blood disorders and cancers.
$19.51 (as of 2026-07-22) · market cap $1.1B
-
ANAPTYSBIO INCANABHealth Care
AnaptysBio is an immunotherapy company generating revenue from blockbuster royalties (Jemperli with GSK, imsidolimab with Vanda) while pursuing its own…
$52.61 (as of 2026-07-22) · market cap $1.6B
-
EVOMMUNE INCEVMNHealth Care
Evommune is a clinical-stage biotechnology company developing novel treatments for inflammatory diseases, currently advancing a pipeline of product candidates…
$11.40 (as of 2026-07-22) · market cap $439M
-
TENAX THERAPEUTICS INCTENXHealth Care
A Phase 3 development-stage pharmaceutical company developing novel cardiopulmonary therapies, primarily levosimendan for pulmonary hypertension and imatinib…
$14.79 (as of 2026-07-22) · market cap $418M
Not quite? Describe exactly what you want →
Peers are AVALYN PHARMA INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: AVALYN PHARMA INC (AVLN).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.